Business Context and Reporting Period
This Form 8-K Current Report was filed by PUMA BIOTECHNOLOGY, INC. on November 6, 2018. The filing reports the appointment of a new Chief Financial Officer and the transition of the principal financial and accounting officer roles.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes
On November 5, 2018, Maximo F. Nougues joined the Company as Chief Financial Officer. Effective November 6, 2018, he assumed the roles of principal financial officer and principal accounting officer, succeeding Charles R. Eyler. Mr. Eyler is expected to remain as Senior Vice President, Finance & Administration and Treasurer until his planned retirement in the first quarter of 2019.
Management Commentary and Compensation Arrangements
Mr. Nougues' employment is governed by a letter agreement with the following terms:
- Base Salary: $445,000 annually.
- Annual Bonus: Target of 40% of base salary.
- Signing Bonus: $550,000 payable within 20 days of commencement.
- Clawback Provisions: If terminated for "cause" or without "good reason" before the fourth anniversary, a portion of the signing bonus must be repaid (100% in year 1, 75% in year 2, 50% in year 3, 25% in year 4).
- Equity: Option to purchase 90,000 shares of common stock under the 2017 Inducement Plan. Vesting is 1/3 on the first anniversary and 1/36 monthly thereafter.
- Severance: In the event of termination without cause or for good reason, the executive is entitled to 12 months of base salary, up to 12 months of healthcare continuation, and full vesting of equity if termination occurs within 18 months of a change in control.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price of the 90,000 stock options granted to Mr. Nougues.
- Confirm the specific definitions of "cause" and "good reason" in the employment agreement to understand termination risks.
- Review the timeline for Charles R. Eyler's planned retirement in Q1 2019.
- Assess the impact of the $550,000 signing bonus on the company's immediate cash flow.